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Abstract
Introduction: An increased risk of vertebral fracture (VF) is one of the extra-articular manifestations of
spondyloarthropathy (SpA). The prevalence of moderate to severe VFs visualized by radiography (Rx) in patients with
SpA in daily practice is unknown until imaging of the full spine is available, as most VFs do not present with clinical
signs and symptoms of an acute fracture.
Methods: We evaluated the prevalence of VFs (>25 % loss in height) on available Rx and dual-energy X-ray
absorptiometry (DXA) images in 390 consecutive patients with SpA in daily practice. We assessed their association with
disease characteristics, bone mineral density, the modified Stoke Ankylosing Spondylitis Spinal Score, and history of trauma.
Results: Forty-six patients (11.8 %) had Rx VF (56.4 % men, 93.5 % in the thoracic spine), and 44.5 % had multiple VFs.
Compared with patients without VF, patients with VF were older (52.2 vs. 47.3 years, p < 0.01; range 25–84 years), had
lower femoral neck T-scores (−1.1 vs. −0.7; p < 0.05), and had a marginally higher modified Stoke Ankylosing Spondylitis
Spinal Score (11.7 vs. 7.0; p = 0.06). Among patients with VFs, 15.2 % had a history of trauma with acute back pain
(p < 0.001 vs. no VF). The reliability of DXA for diagnosing radiographic VFs was high (κ 0.90).
Conclusions: Moderate to severe VFs are found inmore than 10% of patients with SpA before the age of 40 years in 5 % of
women and 9% inmen. Most VFs are located in the thoracic region, are related to low femoral neck bonemineral density
and to stiffening of the spine, and are only rarely related to trauma history. DXA is a useful alternative for diagnosing VFs.
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Introduction
An increased risk of vertebral fracture (VF) is one of the
extra-articular manifestations of ankylosing spondylitis
(AS) [1, 2] and other spondyloarthropathies (SpAs) [3,
4]. In population studies, it has been shown that the risk
of radiographic and clinical VFs is increased in patients
with AS [3, 5–9], even early in the disease [6, 10], and is
also increased in those with inflammatory bowel disease
(IBD) [3] and psoriatic arthritis (PsA) [4]. The prevalence
of VFs has been studied in several surveys including 22–
158 patients with AS in whom the prevalence of radio-
graphic VFs ranged from 1.4 % to 58.0 %. Nevertheless,
criteria for patient selection were variable in these studies
(consecutive patients or patients selected on the basis of
disease activity, occiput to wall distance (OWD), sex or
age, and including clinical VFs or systematic evaluated
morphometric VFs), as were the criteria for VF diagnosis
(variable thresholds of vertebral height loss) [10–14].
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Based on the increased rate of VF in AS, imaging of
the spine is advocated in cases of significant change in
the course of the disease [15, 16]. However, most VFs do
not present with the clinical signs and symptoms of an
acute fracture and are overlooked when back pain is
interpreted as a disease flare of spondylitis. No data are
available on the relationship between history of trauma
and acute or chronic back pain in SpA.
Imaging of the spine is most often performed with
conventional radiography (Rx), but Vertebral Fracture
Assessment (VFA) using dual-energy X-ray absorpti-
ometry (DXA) technology is of increasing interest be-
cause of its low radiation dose and high negative
predictive value (NPV) [17], and it has also been studied
in AS [13, 18, 19].
We evaluated the presence of VF using Rx and VFA in
a non-academic rheumatology practice in a large cohort
of patients with SpA in relation to disease characteris-
tics, bone mineral density (BMD), syndesmophytes, and
history of back pain and trauma.
Methods
Study population
A total of 390 consecutive ambulatory patients with SpA
who were seen by six rheumatologists in an ambulatory
non-academic rheumatology clinic were included be-
tween July 2013 and December 2013.
Diagnoses of AS, undifferentiated SpA, PsA, and IBD
were made by the treating rheumatologists according to
the criteria set forth in national and international guide-
lines [20]. This study was approved by the medical ethics
committee of Ziekenhuisnetwerk Antwerpen (Belgium),
and all patients provided informed consent before
participation.
Bone mineral density
BMD was measured in the lumbar spine (anteroposterior
projection), femoral neck, and total hip using DXA with
standard procedures as recommended by the manu-
facturer (Lunar Prodigy Primo BX-1 L enCORE device,
version 12.30; GE Healthcare Life Sciences, Chalfont
St. Giles, UK). VFA imaging was performed using soft-
ware provided by the manufacturer for this device.
Radiographic assessment and scoring
Lateral images of the thoracic and lumbar spine were
semiquantitatively evaluated according to the Genant
score for anterior, middle, and posterior height using
available digital Rx and VFA images [21, 22]. VFA was
performed using a semiquantitative (SQ) technique.
Each Rx and VFA image was inspected visually by the
treating rheumatologist to decide whether it contained a
fracture in any of the visualized vertebrae and assigned a
grade based on the Genant SQ scale, where grade 2
(moderate) is a reduction of 26–40 % and grade 3 (severe)
a reduction of over 40 %. In case of doubt, vertebral
heights were measured using the digital measuring device
supplied by the provider of the digital Rx system.
Only vertebral deformities >25 % were considered as
a VF (grades 2 and 3), as this degree of deformity in-
creases the specificity compared with a lesser degree
of deformity [23].
On lateral spine radiographs, the cervical, lumbar and
thoracic vertebrae were scored using the modified Stoke
Ankylosing Spondylitis Spinal Score (mSASSS) as 0
(normal), 1 (erosion, sclerosis, or squaring), 2 (obvious
syndesmophyte), and 3 (total bone bridge) [16]. The
mSASSS according to Assessment of SpondyloArthritis
international Society includes scoring of radiographs at
the cervical and lumbar spine (range 0–72). In addition,
the same scoring method was also used for the thoracic
spine, and additional mSASSS was calculated for both
the thoracic spine (range 0–72) and total spine (range
0–144).
Each of the six experienced rheumatologists performed
scoring of mSASSS on radiographs and VFs on the
radiographs and VFAs of their own patients. They were
all experienced and trained in scoring VF, as well as in
patients with SpA, at the yearly bone curriculum meet-
ings of the Osteoporosis Working Group of the Royal
Belgian Rheumatology Society. Therefore, no intra- or
interreader reliability was tested.
Disease characteristics
Disease characteristics of patients included the Bath
Ankylosing Spondylitis Disease Activity Index (BASDAI),
Bath Ankylosing Spondylitis Functional Index (BASFI),
Ankylosing Spondylitis Disease Activity Score (ASDAS),
OWD, presence of human leukocyte antigen B27
(HLA-B27), and serum erythrocyte sedimentation rate
(ESR) and C-reactive protein (CRP). All patients were
asked about a history of falls and trauma and subse-
quent acute or chronic back pain.
Statistical analysis
We report descriptive statistics and comparisons be-
tween patients with and without a VF using analysis of
variance (ANOVA) for continuous variables and cross-
tabulation for dichotomous variables.
Univariable and multivariable logistic regression ana-
lyses were used to estimate the effects of factors that
were significantly different between patients with and
without a VF on the likelihood [expressed as odds ratio
(OR) with 95 % confidence interval (CI)] that partici-
pants had a radiographic VF.
A reliability analysis using the κ statistic was per-
formed to determine consistency between VFA and Rx
in diagnosing VF. For the diagnostic value of VFA in
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identifying radiographic VF, we calculated sensitivity,
specificity, positive predictive value (PPV), and NPV.
Calculations were performed using IBM SPSS version 22
software (IBM, Armonk, NY, USA).
Results
Study population
The basic characteristics and BMD of the 390 patients
with SpA are shown in Table 1. These included 175
(44.9 %) men and 215 (55.1 %) women, 286 (73.3 %) of
whom had AS, 40 (10.3 %) of whom had PsA, 18 (4.6 %)
of whom had IBD, and 46 (11.8 %) of whom had undif-
ferentiated SpA. The patients’ mean age was 47.9 years
[standard deviation (SD) 11.9, range 21–84 years]. The
mean time since first symptoms was 14.6 years (SD 10.7,
range 1–60 years), and the mean time since diagnosis
was 10.8 years (SD 9.9, range: 0–60 years). The mean
difference between symptoms and diagnosis was 3.9 years
(SD 5.8, range 0–33 years). HLA-B27 was present in 203
(62.8 %) of the 323 patients in whom this was evaluated.
In addition, 168 (43.1 %) of the patients had undergone
treatment with tumor necrosis factor blockers at the
time of the survey.
The majority of patients had normal BMD (T-score −1.0
or higher) in the spine (79.7 %) and in the femoral neck
(59.5 %), whereas 17.2 % and 36.4 % had a T-score be-
tween −1 and −2.5, respectively. Only a minority of pa-
tients had a T-score −2.5 or lower (3.1 % in the spine and
4.1 % in the femoral neck). BMD decreased with age in
the femoral neck in women (−0.46; p < 0.001) and men
(−0.31; p < 0.001), as well as in the spine in women (−0.26;
p < 0.001), but it increased with age in the spine in men
(0.27; p < 0.001) (Fig. 1).
The classical mSASSS (cervical + lumbar spine) was
7.6 (SD 15.9, range 0–72). The mSASSS for the thoracic
spine was 10.6 (range 0–72), resulting in a total spine
mSASSS score of 18.1 (SD 34.4, range 0–144). mSASSS >0
were found in the cervical spine in 30.1 % of patients, in
the thoracic spine in 43.6 %, in the lumbar spine in 38.2 %,
in the cervical and lumbar spine combined in 45.1 %, and
in the total spine in 55.1 %.
By Rx, moderate to severe VFs were identified in 46
patients, of whom 25 (54.3 %) were men. Twenty pa-
tients (43.5 %) had more than one VF (18 had 2 VFs and
2 had 3 VFs), resulting in a total of 68 VFs. Of the 68
VFs, 62 (91.2 %) were located in the thoracic spine
(Fig. 2). The prevalence was highest in IBD (22.2 %),
followed by 12.2 % in AS and 10.0 % in PsA, and lowest
in undifferentiated SpA (6.5 %).
Comparisons between patients with and without VF
are shown in Table 2. Compared with patients without
VF, patients with a VF were older (52.2 vs. 47.3 years,
range 25–84 years; p < 0.01). They had a lower T-score
in the femoral neck (−1.00 vs. −0.70; p < 0.05) and total
hip (−0.74 vs. −0.27; p < 0.05), more peripheral joint
disease (4.4 vs. 3.5; p < 0.05), a marginally higher classical
(cervical + lumbar) mSASSS (11.7 vs. 7.0; p = 0.06),
and a significantly higher thoracic mSASSS (16.2 vs.
9.8; p < 0.05).
Compared with patients with an mSASSS score of 0 at
the level of BMD measurement (L2-L4), patients with
mSASSS scores >0 had a significantly higher T-score in
the spine (0.47 vs. 0.12; p = 0.50). In contrast, the T-
score was significantly lower in the femoral neck (−1.01
vs. −0.60; p < 0.001) and in the total hip (−0.65 vs. −0.22;
p < 0.001).
Univariable logistic regression analysis revealed the
OR for VF (based on the significant differences in
Table 2): age (OR 1.35 per 10-year increase, 95 % CI
1.08–1.62) (Fig. 3), duration of symptoms (OR 1.35 per
10-year increase, 95 % CI 1.08–1.61), thoracic mSASSS
(OR 1.13 per 10-point increase, 95 % CI 1.00–1.25), and
femoral neck T-score (OR 1.38 per 1 SD decrease, 95 %
CI 1.01–1.88). In multivariable regression analysis in-
cluding these factors, only age remained significant, with
an OR of 1.35 (95 % CI 1.08–1.62) per 10-year increase
in age.
Table 1 Basic characteristics of included patients with
spondyloarthritis (n = 390)
Characteristics Meana Rangeb
Age, yr 47.9 ± 11.9 21–84
Symptom duration, yr 14.6 ± 10.7 1–60
Disease duration, yr 10.8 ± 9.9 0–60
ESR, mm/h 9.0 ± 10.4 0–86
CRP, mg/L 3.8 ± 6.3 0–60
BASDAI 4.3 ± 2.3 0–10
BASFI 5.0 ± 8.0 0–83
ASDAS-ESR 2.2 ± 1.0 0–5
ASDAS-CRP 2.2 ± 1.1 0–5
mSASSS
Cervical spine 3.7 ± 9.2 0–42
Thoracic spine 10.6 ± 20.4 0–72
Lumbar spine 3.9 ± 8.0 0–30
Cervical + lumbar spine 7.6 ± 15.9 0–72
Total spine 18.1 ± 34.4 0–144
T-score
Lumbar spine −0.2 ± 1.7 −4.3 to ±10.4
Femoral neck −0.7 ± 1.1 −3.8 to ±4.7
Total hip −0.4 ± 1.1 −3.2 to ±4.9
ESR erythrocyte sedimentation rate, CRP C-reactive protein, BASDAI Bath
Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis
Functional Index, ASDAS Ankylosing Spondylitis Disease Activity Score,
mSASSS modified Stoke Ankylosing Spondylitis Spinal Score
aCharacteristics of patients with SpA are presented as mean absolute
number ± standard deviation
bRange of absolute numbers for a given characteristic
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A history of falls was reported by 15.1 % of patients,
17.4 % with and 14.8 % without a VF (not statistically
significant). A history of trauma with subsequent acute
back pain was reported by 15.2 % of patients, 15.2 %
with and 2.6 % without a VF (p = 0.001). A history of
trauma with subsequent chronic back pain was reported
by 1.3 % of patients, 8.7 % with and 0.3 % without a VF
(p = 0.001).
One patient had a history of spontaneous dorsal arch
fracture at T10 without previous trauma, which was
Fig. 1 Correlation between bone mineral density (of the femoral neck and lumbar spine) and age. Bone mineral density of patients with SpA is
represented as T-score. T-scores are shown in the (a) femoral neck and (b) lumbar spine for both women (left) and men (right) according to their
age (years). Lines represent the 95 % confidence intervals
Fig. 2 Prevalence of vertebral fractures (VFs) in the thoracic and lumbar spine of patients with spondyloarthropathy (SpA). The occurrence of VFs
is represented as the absolute number of patients with SpA with VFs in either the thoracic (T5-T12) or lumbar part of the spine (L1-L5) (black).
The absolute number of patients with SpA with only one VF located in the thoracic or lumbar spine is shown with light gray bars. Dark gray bars
represent patients with SpA with more than one VF located in the thoracic or lumbar spine
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diagnosed only after bone scintigraphy and magnetic
resonance imaging and that healed spontaneously with-
out complications other than temporarily increased back
pain. Three patients (0.8 %) had a history of VF with
neurologic complications: two after a cervical fracture
and one after a lumbar fracture.
The reliability of Rx and VFA for diagnosing VF was
found to be κ = 0.898 (standard error 0.036; p < 0.001)
(Table 3). Rx VF could not be diagnosed on the basis of
VFA in six patients, because the VFA images were of in-
sufficient quality. In two patients, VFs were diagnosed
with the use of VFA, and the VFs were also present on
radiographs but with a deformity of <25 % on Rx.
The analysis of the diagnostic value of VFA to detect
VFs identified on Rx indicated sensitivity of 87 % (95 %
CI 74–95 %), with specificity of 99 % (95 % CI 98–
100 %), PPV of 95 % (95 % CI 84–99 %), and NPV of
98 % (95 % CI 96–99 %).
Discussion
In this large survey of VFs in 390 men and women with
SpA, we found >10 % prevalence of moderate to severe
VFs, already before the age of 30 years and within 5 years
of symptoms.
The pathophysiology of VFs in SpA is complex
[13, 24–26]. In AS, markers of bone resorption are in-
creased in active disease and are related to low BMD and
bone loss in the femoral neck and in the spine [27, 28].
Markers of bone formation are mostly normal in AS and
not correlated with BMD [27]. Low BMD and bone loss
Table 2 Basic characteristics of patients with spondyloarthritis
without (n = 344) and with (n = 46) one or more radiographic






(n = 344) (n = 46)
Age, yrb 47.3 ± 11.6 52.2 ± 13.1 <0.01
Symptom duration, yrc 14.1 ± 10.4 18.5 ± 12.4 <0.01
Disease duration, yrd 10.5 ± 9.6 12.5 ± 12.1 ns
ESR, mm/h 9.2 ± 10.7 8.0 ± 8.1 ns
CRP, mg/L 4.0 ± 6.5 2.9 ± 3.8 ns
BASDAI 4.3 ± 2.3 4.7 ± 2.2 ns
BASFI 5.0 ± 8.5 4.9 ± 2.9 ns
ASDAS-ESR 2.2 ± 1.0 2.4 ± 0.9 ns
ASDAS-CRP 2.2 ± 1.0 2.3 ± 1.0 ns
OWD 1.3 ± 4.2 2.5 ± 5.5 0.09
mSASSS
Cervical spine 3.4 ± 8.5 5.8 ± 13.2 0.10
Thoracic spine 9.8 ± 19.6 16.2 ± 25.1 <0.05
Lumbar spine 3.6 ± 7.6 6.0 ± 10.3 <0.07
Cervical + lumbar spine 7.0 ± 15.0 11.7 ± 21.6 0.06
Total spine 16.8 ± 32.8 27.9 ± 43.5 <0.05
T-score
Lumbar spine 0.25 ± 1.70 0.13 ± 1.50 ns
Femoral neck −0.70 ± 1.06 −1.00 ± 0.97 <0.05
Total hip −0.34 ± 1.09 −0.59 ± 1.04 ns
ESR erythrocyte sedimentation rate, CRP C-reactive protein, BASDAI Bath
Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis
Functional Index, ASDAS Ankylosing Spondylitis Disease Activity Score,
mSASSS modified Stoke Ankylosing Spondylitis Spinal Score, TNF tumor necrosis
factor, ns not statistically significant, VF vertebral fracture, OWD Occiput to
wall distance
Characteristics of patients with spondyloarthritis (SpA) are represented as
mean absolute number ± standard deviation
aMeans of characteristics were compared between patients with SpA without
and with VF using analysis of variance. p value <0.05 was considered
statistically significant.
bMean age ± standard deviation in years
cMean symptom duration ± standard deviation in years; time since
first symptoms
dMean disease duration ± standard deviation in years; time since diagnosis
Fig. 3 Prevalence of vertebral fractures (VFs) according to age and sex
of patients with spondyloarthropathy (SpA). The prevalence of VFs is
shown as the percentage of men (gray bars) or women (black bars) of
the total number of patients with SpA with VFs in three different age
groups. Age groups were 20–39 years, 40–59 years, and 60 years
and older
Table 3 Analysis of congruence between conventional
radiography and Vertebral Fracture Assessment for diagnosing
vertebral fractures
Rx
VF No VF Total
VFA VF 40 2 42
No VF 6 342 348
Total 46 344 390
VF vertebral fracture, VFA Vertebral Fracture Assessment
Patients with spondyloarthritis with or without VF who were diagnosed by
radiography (Rx) or by VFA using dual X-ray energy absorptiometry are
represented as absolute numbers. Agreement between VFA and Rx was
excellent (κ = 0.898, standard error 0.036; p < 0.001). The diagnostic value of VFA
in identifying Rx VF indicated sensitivity of 87 % [95 % confidence interval (CI)
74–95 %], specificity of 99 % (95 % CI 98–100 %), positive predictive value of
95 % (95 % CI 84–99 %), and negative predictive value of 98 % (95 % CI 96–99 %)
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have been documented in the spine [by DXA and quan-
titative computed tomography (QCT)] and in the hip
(by DXA) [29, 30]. Later in the course of AS, BMD is
decreased in the hip (as shown by DXA) and within
the vertebrae (by QCT), but not in the lumbar spine
(by DXA). This is due to intervertebral syndesmophyte
formation, periosteal bone formation with squaring of the
vertebrae, ankylosis of the facet joints, and calcification of
the perivertebral ligaments (by QCT) [29, 30].
Using high-resolution peripheral QCT, it has been
shown that patients with AS who have osteoporosis also
have a decrease in bone volume density and in cortical
thickness in the distal radius and distal tibia, which cor-
related with trabecular volumetric BMD in the lumbar
spine using QCT [31]. These studies suggest that pa-
tients with AS have a generalized loss of trabecular bone
density. The clinical consequence is that this low BMD
and bone loss are measurable by DXA in the spine and
hip early in the disease, but only in the hip later in the
disease course [24, 25].
Interestingly, in this study, the presence of VF was re-
lated to mSASSS and marginally to BMD measured by
DXA in the femoral neck. This indicates that, in addition
to a low BMD, an altered biomechanical performance of
the vertebrae by the stiffening of the spine contributes
to the occurrence of VF [13, 24, 25]. These results fur-
ther support the European League Against Rheumatism
(EULAR) recommendations on imaging in SpA, which
state that in patients with axial SpA without syndesmo-
phytes in the lumbar spine visualized by conventional
Rx, osteoporosis should be assessed by hip DXA and
anteroposterior spine DXA. In patients with syndesmo-
phytes in the lumbar spine visualized by conventional
Rx, osteoporosis should be assessed by hip DXA supple-
mented by either spine DXA in lateral projection or pos-
sibly QCT of the spine [32].
VFs do not occur uniformly along the spine, but, as
shown in postmenopausal and senile osteoporosis, they
occur more often in the midthoracic and thoracolumbar
regions than elsewhere [33, 34], which is likely attri-
butable to biomechanical factors. Apart from loading
(body height, weight, muscle forces, movements such as
bending), other factors play a role in VF, such as spinal
curvature and the heterogeneity of BMD between verte-
brae [35]. Furthermore, a wedged thoracic VF increases
the biomechanical stresses in other vertebrae [36]. In
view of the relationship between VF and mSASSS in this
and other studies [14], stiffening of the spine in SpA also
could contribute to VF risk. Segmental or generalized
syndesmophyte formation (bamboo spine) transforms
the flexible spine in a long stiff bone (with intravertebral
osteoporosis as shown with computed tomography) with
decreased biomechanical competence. Stiffening of the
spine in AS can also explain why VFs in AS occur at
unusual locations (cervical spine) with unusual charac-
teristics (e.g., transdiscal and horizontal transvertebral
fractures and fractures of the dorsal arch structures of
the vertebrae, which was reported by one of our
patients) and with severe neurologic deficits, which
occurred in three patients (0.8 %) [24].
Patients with a VF more often had a history of acute
and chronic back pain after trauma than did patients
without a VF. However, this occurred only in a minority
of patients with a VF (one of six patients), suggesting
that most VFs in SpA are not the result of trauma. The
clinical consequence is that a history of trauma helps to
identify only a limited number of patients with a VF.
According to the ASAS/EULAR recommendations, im-
aging of the spine is advocated in AS in cases of a sig-
nificant change in the course of the disease [15, 16].
However, on the basis of the high prevalence of subclin-
ical VFs, this recommendation could need adaption, as
VFs can be diagnosed only when imaging of the spine is
performed and can be present without a history of
trauma or typical signs and symptoms of an acute
fracture.
The agreement between digitized Rx and VFA in
diagnosing VFs, as well as the high NPV [17–19], is of
clinical interest. VFA missed six (12.5 %) of the radio-
graphic VFs. This indicates that in the majority of pa-
tients with SpA, VFA will enable diagnosis of VFs using
a much lower level of radiation than Rx. Earlier studies
showed less congruent results, but this could have been
due to measuring vertebral heights using a less reli-
able magnification loop on plain radiographic films
instead of electronic aids on digitized radiographs in
this study [18, 19].
In view of its high NPV, VFA allows selection of pa-
tients who will or who will not need Rx for diagnosing
VFs [17–19, 23]. A prevalent VF is a strong predictor of
future VFs and non-VFs. No fracture prevention studies
are available in SpA. It is therefore indicated that
patients with SpA and early bone loss, osteoporosis,
and/or a prevalent VF should be considered candidates
for antiresorptive drugs to prevent fractures.
The strength of this study is the large sample collec-
tion and the representativeness of the patient group in a
peripheral non-academic rheumatology center, including
a broad range of ages and representing both sexes. Inter-
estingly, we found the overall prevalence of SpAs to be
as common in women as in men. The dominant male
prevalence in AS is well accepted. However, the gender
distribution in our survey is in line with the finding that,
in recent years, the gender ratio approached 1:1 in an
AS patient survey in Germany [37] and in a population
survey in the south of Sweden for SpAs [38]. This find-
ing has been included in the ASAS mission statement
on epidemiology of AS [39]. The reported data regarding
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prevalence of PsA according to gender is conflicting
[38]. The incidence of Crohn’s disease is similar between
women and men, but the prevalence of IBD with SpA is
unknown [40].
The finding that VFA using DXA has high sensitivity,
specificity, PPV, and NPV compared with Rx is another
strength with possible clinical consequences for screen-
ing. It indicates that VFA can be used as a prescreening
tool for the presence of a VF in SpA, limiting the use of
radiographs to patients with a VF on VFA, or when VFA
is not of adequate quality to evaluate VFs.
A limitation of the study is the small number of pa-
tients with PsA and IBD. Furthermore, we chose only
VFs with a deformity >25 % and not smaller deformities,
as this would have increased sensitivity but decreased
specificity for diagnosing a VF [23]. Therefore, the preva-
lence of VFs is even higher in this population when mild
deformities are also included [14]. Last, the relationship
between a history of trauma and the presence of VF
should be interpreted with caution, as there is a pos-
sibility of recall bias of traumas.
Conclusions
Moderate to severe VFs are found in more than 10 % of
patients with SpA, already before the age of 40 years in
5 % of women and 9 % of men and within 5 years of
disease symptoms. Most VFs are located in the thoracic
region, are subclinical, and are related to low femoral
neck BMD and stiffening of the thoracic spine. VFA is
helpful in selecting patients in whom Rx should be per-
formed to diagnose a VF.
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